secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003866
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere reports preliminary Q4 2023 net product sales ~$40M, FILSPARI sales $15M; cash $567M
--------------------------------------------------------------------------------

- Preliminary Q4 2023 net product sales from continuing ops ~$40M; FY 2023 ~$128M.
- FILSPARI net sales Q4 ~$15M (launch-to-date ~$30M); 459 new patient start forms in Q4.
- Cash, cash equivalents & marketable securities ~$567M; expected to fund operations into 2028.
- sNDA for full FILSPARI approval in IgAN on track for Q1 2024; CHMP opinion also expected Q1 2024.
- Pivotal Phase 3 HARMONY study for pegtibatinase in HCU initiated; topline results expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/d87492d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer